However, as receptor occupancy was determined using an in vitro assay in isolated donor cells overexpressing LAG-3, a higher dose of INCAGN02385 (350 mg Q2W) was selected to account for potentially lower drug availability within the tumor. This evidence concerns the gene LAG3 and neoplasm.